ALK-positive anaplastic large cell lymphoma limited to the skin: Clinical, histopathological and molecular analysis of 6 pediatric cases. A report from the ALCL99 study

Haematologica

Volumn 98, Issue 1, 2013, Pages 50-56

  Oschlies, Ilske ^a   Lisfeld, Jasmin ^b   Lamant, Laurence ^c   Nakazawa, Atsuko ^d   d'Amore, Emanuele S G ^e   Hansson, Ulrika ^f   Hebeda, Konnie ^g   Simonitsch Klupp, Ingrid ^h   Maldyk, Jadwiga ⁱ   Müllauer, Leonhard ^h   Tinguely, Marianne ^j   Stücker, Markus ^k   LeDeley, Marie Cecile ^l   Siebert, Reiner ^a   Reiter, Alfred ^b   Brugières, Laurence ^l   Klapper, Wolfram ^a   Woessmann, Wilhelm ^b  

^a UNIVERSITY OF KIEL   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c CHU PURPAN   (France)

^d NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^e SAN BORTOLO HOSPITAL   (Italy)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁱ Department of Pathology   (Poland)

^j UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^k RUHR UNIVERSITY BOCHUM   (Germany)

^l INSTITUT GUSTAVE ROUSSY   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CD30 ANTIGEN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; MALE; MULTICENTER STUDY (TOPIC); PROTEIN EXPRESSION; SCHOOL CHILD; SKIN DEFECT;

ADOLESCENT; CHILD; FEMALE; HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MALE; RECEPTOR PROTEIN-TYROSINE KINASES; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84872073488     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.065664     Document Type: Article

References (41)

1. Swerdlow SH, Campo E, Harris N, Jaffe E, Pileri S, Stein H, et al. WHO Classification of Tumors of the Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008.
2. Burkhardt B, Zimmermann M, Oschlies I, Niggli F, Mann G, Parwaresch R, et al. The impact of age and gender on biology, clinical features and treatment outcome of nonHodgkin lymphoma in childhood and adolescence. Br J Haematol. 2005;131(1):39-49.
3. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124-30.
4. Seidemann K, Tiemann M, Schrappe M, Yakisan E, Simonitsch I, Janka-Schaub G, et al. Short-pulse B-non-Hodgkin lymphomatype chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-FrankfurtMunster Group Trial NHL-BFM 90. Blood. 2001;97(12):3699-706.
5. Brugieres L, Le Deley MC, Rosolen A, Williams D, Horibe K, Wrobel G, et al. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol. 2009;27(6):897-903.
6. Le Deley MC, Reiter A, Williams D, Delsol G, Oschlies I, McCarthy K, et al. Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup study. Blood. 2008;111(3):1560-6.
7. Reiter A, Schrappe M, Parwaresch R, Henze G, Muller-Weihrich S, Sauter S, et al. Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Munster Group. J Clin Oncol. 1995;13(2):359-72.
8. Williams DM, Hobson R, Imeson J, Gerrard M, McCarthy K, Pinkerton CR. Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children's Cancer Study Group chemotherapy regimens. Br J Haematol. 2002;117(4):812-20.
9. Brugieres L, Deley MC, Pacquement H, Meguerian-Bedoyan Z, Terrier-Lacombe MJ, Robert A, et al. CD30(+) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood. 1998;92(10):3591-8.
10. Damm-Welk C, Klapper W, Oschlies I, Gesk S, Rottgers S, Bradtke J, et al. Distribution of NPM1-ALK and X-ALK fusion transcripts in paediatric anaplastic large cell lymphoma: a molecular-histological correlation. Br J Haematol. 2009; 146(3):306-9.
11. Bekkenk MW, Geelen FA, van Voorst Vader PC, Heule F, Geerts ML, van Vloten WA, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000; 95(12):3653-61.
12. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768-85.
13. Kempf W, Pfaltz K, Vermeer MH, Cozzio A, Ortiz-Romero PL, Bagot M, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011; 118(15):4024-35.
14. Wada DA, Law ME, Hsi ED, Dicaudo DJ, Ma L, Lim MS, et al. Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies. Mod Pathol. 2011;24(4):596-605.
15. Feldman AL, Dogan A, Smith DI, Law ME, Ansell SM, Johnson SH, et al. Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood. 2011;117(3):915-9.
16. Lamant L, McCarthy K, d'Amore E, Klapper W, Nakagawa A, Fraga M, et al. Prognostic Impact of Morphologic and Phenotypic Features of Childhood ALKPositive Anaplastic Large-Cell Lymphoma: Results of the ALCL99 Study. J Clin Oncol. 201;29(35):4669-76.
17. Salaverria I, Philipp C, Oschlies I, Kohler CW, Kreuz M, Szczepanowski M, et al. Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. Blood. 2011; 118(1):139-47.
18. Ventura RA, Martin-Subero JI, Jones M, McParland J, Gesk S, Mason DY, et al. FISH analysis for the detection of lymphomaassociated chromosomal abnormalities in routine paraffin-embedded tissue. J Mol Diagn. 2006;8(2):141-51.
19. Damm-Welk C, Busch K, Burkhardt B, Schieferstein J, Viehmann S, Oschlies I, et al. Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK positive anaplastic large cell lymphoma. Blood. 2007;110(2):670-7.
20. Brugieres L, Le Deley MC, Rosolen A, Williams D, Horibe K, Wrobel G, et al. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol. 2009;27(6):897-903.
21. Le Deley MC, Rosolen A, Williams DM, Horibe K, Wrobel G, Attarbaschi A, et al. Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. J Clin Oncol. 2010; 28(25):3987-93.
22. Reiter A, Schrappe M, Tiemann M, Parwaresch R, Zimmermann M, Yakisan E, et al. Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive BerlinFrankfurt-Munster group studies. J Clin Oncol. 1994;12(5):899-908.
23. Benner MF, Willemze R. Applicability and prognostic value of the new TNM classification system in 135 patients with primary cutaneous anaplastic large cell lymphoma. Arch Dermatol. 2009;145(12):1399-404.
24. Tomaszewski MM, Moad JC, Lupton GP. Primary cutaneous Ki-1(CD30) positive anaplastic large cell lymphoma in childhood. J Am Acad Dermatol. 1999;40(5 Pt 2):857-61.
25. Fink-Puches R, Chott A, Ardigo M, Simonitsch I, Ferrara G, Kerl H, et al. The spectrum of cutaneous lymphomas in patients less than 20 years of age. Pediatr Dermatol. 2004;21(5):525-33.
26. Kumar S, Pittaluga S, Raffeld M, Guerrera M, Seibel NL, Jaffe ES. Primary cutaneous CD30-positive anaplastic large cell lymphoma in childhood: report of 4 cases and review of the literature. Pediatr Dev Pathol. 2005;8(1):52-60.
27. Santiago-et-Sanchez-Mateos D, Hernandez-Martin A, Colmenero I, Mediero IG, Leon A, Torrelo A. Primary cutaneous anaplastic large cell lymphoma of the nasal tip in a child. Pediatr Dermatol. 2011;28(5):570-5.
28. Hung TY, Lin YC, Sun HL, Liu MC. Primary cutaneous anaplastic large cell lymphoma in a young child. Eur J Pediatr. 2008;167(1):111-3.
29. Lamant L, Pileri S, Sabattini E, Brugieres L, Jaffe ES, Delsol G. Cutaneous presentation of ALK-positive anaplastic large cell lymphoma following insect bites: evidence for an association in five cases. Haematologica. 2010;95(3):449-55.
30. Benharroch D, Meguerian-Bedoyan Z, Lamant L, Amin C, Brugieres L, TerrierLacombe MJ, et al. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood. 1998; 91(6):2076-84.
31. ten Berge RL, Oudejans JJ, Dukers DF, Meijer CJ. Anaplastic large cell lymphoma: what's in a name? J Clin Pathol. 2001; 54(6):494-5.
32. ten Berge RL, Oudejans JJ, Ossenkoppele GJ, Pulford K, Willemze R, Falini B, et al. ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination. J Clin Pathol. 2000;53(6):445-50.
33. Beylot-Barry M, Groppi A, Vergier B, Pulford K, Merlio JP. Characterization of t(2;5) reciprocal transcripts and genomic breakpoints in CD30+ cutaneous lymphoproliferations. Blood. 1998;91(12):4668-76.
34. Herbst H, Sander C, Tronnier M, Kutzner H, Hugel H, Kaudewitz P. Absence of anaplastic lymphoma kinase (ALK) and Epstein-Barr virus gene products in primary cutaneous anaplastic large cell lymphoma and lymphomatoid papulosis. Br J Dermatol. 1997;137(5):680-6.
35. Liu HL, Hoppe RT, Kohler S, Harvell JD, Reddy S, Kim YH. CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol. 2003; 49(6):1049-58.
36. Kadin ME, Pinkus JL, Pinkus GS, Duran IH, Fuller CE, Onciu M, et al. Primary cutaneous ALCL with phosphorylated/activated cytoplasmic ALK and novel phenotype: EMA/MUC1+, cutaneous lymphocyte antigen negative. Am J Surg Pathol. 2008; 32(9):1421-6.
37. Sasaki K, Sugaya M, Fujita H, Takeuchi K, Torii H, Asahina A, et al. A case of primary cutaneous anaplastic large cell lymphoma with variant anaplastic lymphoma kinase translocation. Br J Dermatol. 2004; 150(6):1202-7.
38. Su LD, Schnitzer B, Ross CW, Vasef M, Mori S, Shiota M, et al. The t(2;5)-associated p80 NPM/ALK fusion protein in nodal and cutaneous CD30+ lymphoproliferative disorders. J Cutan Pathol. 1997;24(10):597-603.
39. Hosoi M, Ichikawa M, Imai Y, Kurokawa M. A case of anaplastic large cell lymphoma, ALK positive, primary presented in the skin and relapsed with systemic involvement and leukocytosis after years of follow-up period. Int J Hematol. 2010; 92(4):667-8.
40. Chan DV, Summers P, Tuttle M, Cooper KD, Cooper B, Koon H, et al. Anaplastic lymphoma kinase expression in a recurrent primary cutaneous anaplastic large cell lymphoma with eventual systemic involvement. J Am Acad Dermatol. 2011; 65(3):671-3.
41. Workshop of the Society for Hematopathology and the European Association for Hematopathology (SH/EAHP) on Cutaneous Lymphomas and Their Mimics. 2011. Proceedings.